The Community for Technology Leaders
RSS Icon
Issue No.03 - May/June (2011 vol.8)
pp: 650-658
James T. Murphy , Dublin City University, Dublin
Ray Walshe , Dublin City University, Dublin
Marc Devocelle , Royal College of Surgeons in Ireland, Dublin
Simulations were carried out to analyze a promising new antimicrobial treatment strategy for targeting antibiotic-resistant bacteria called the \beta-lactamase-dependent prodrug delivery system. In this system, the antibacterial drugs are delivered as inactive precursors that only become activated after contact with an enzyme characteristic of many species of antibiotic-resistant bacteria (\beta-lactamase enzyme). The addition of an activation step contributes an extra layer of complexity to the system that can lead to unexpected emergent behavior. In order to optimize for treatment success and minimize the risk of resistance development, there must be a clear understanding of the system dynamics taking place and how they impact on the overall response. It makes sense to use a systems biology approach to analyze this method because it can facilitate a better understanding of the complex emergent dynamics arising from diverse interactions in populations. This paper contains an initial theoretical examination of the dynamics of this system of activation and an assessment of its therapeutic potential from a theoretical standpoint using an agent-based modeling approach. It also contains a case study comparison with real-world results from an experimental study carried out on two prodrug candidate compounds in the literature.
Antibiotic resistance, agent-based model, prodrug, bacteria, simulation.
James T. Murphy, Ray Walshe, Marc Devocelle, "A Theoretical Analysis of the Prodrug Delivery System for Treating Antibiotic-Resistant Bacteria", IEEE/ACM Transactions on Computational Biology and Bioinformatics, vol.8, no. 3, pp. 650-658, May/June 2011, doi:10.1109/TCBB.2010.58
[1] H.C. Neu, "The Crisis in Antibiotic Resistance," Science, vol. 257, no. 5073, pp. 1064-1073, Aug. 1992.
[2] D.I. Andersson, "Persistence of Antibiotic Resistant Bacteria," Current Opinion in Microbiology, vol. 6, no. 5, pp. 452-456, Oct. 2003.
[3] S.B. Levy and B. Marshall, "Antibacterial Resistance Worldwide: Causes, Challenges and Responses," Nature Medicine, vol. 10, no. 12, pp. S122-S129, Dec. 2004.
[4] F.D. Lowy, "Antimicrobial Resistance: The Example of Staphylococcus aureus," The J. Clinical Investigation, vol. 111, no. 9, pp. 1265-1273, May 2003.
[5] A. Bondi and C.C. Dietz, "Penicillin Resistant Staphylococci," Proc. Soc. for Experimental Biology and Medicine, vol. 60, no. 1, pp. 55-58, 1945.
[6] E. Chain, H.W. Florey, M.B. Adelaide, A.D. Gardner, N.G. Heatley, M.A. Jennings, J. Orr-Ewing, and A.G. Sanders, "Penicillin as a Chemotherapeutic Agent. 1940," Clinical Orthopaedics and Related Research, vol. 295, pp. 3-7, Oct. 1993.
[7] K. Hiramatsu, L. Cui, M. Kuroda, and T. Ito, "The Emergence and Evolution of Methicillin-Resistant Staphylococcus aureus," Trends in Microbiology, vol. 9, no. 10, pp. 486-493, Oct. 2001.
[8] R.M. Klevens, J.R. Edwards, F.C. Tenover, L.C. McDonald, T. Horan, R. Gaynes, and N.N.I.S. System, "Changes in the Epidemiology of Methicillin-Resistant Staphylococcus aureus in Intensive Care Units in US Hospitals, 1992-2003," Clinical Infectious Diseases, vol. 42, no. 3, pp. 389-391, Feb. 2006.
[9] R.M. Klevens, M.A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L.H. Harrison, R. Lynfield, G. Dumyati, J.M. Townes, A.S. Craig, E.R. Zell, G.E. Fosheim, L.K. McDougal, R.B. Carey, S.K. Fridkin, and A.B.C. surveillance (ABCs) MRSA Investigators, The J. Am. Medical Assoc., vol. 298, no. 15, pp. 1763-1771, Oct. 2007.
[10] C.C. Fuda, J.F. Fisher, and S. Mobashery, "Beta-Lactam Resistance in Staphylococcus aureus: The Adaptive Resistance of a Plastic Genome," Cellular and Molecular Life Sciences, vol. 62, no. 22, pp. 2617-2633, Nov. 2005.
[11] J.T. Murphy, R. Walshe, and M. Devocelle, "A Computational Model of Antibiotic-Resistance Mechanisms in Methicillin-Resistant Staphylococcus aureus (MRSA)," J. Theoretical Biology, vol. 254, no. 2, pp. 284-293, Sept. 2008.
[12] J.F. Fisher, S.O. Meroueh, and S. Mobashery, "Bacterial Resistance to Beta-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity," Chemical Rev., vol. 105, no. 2, pp. 395-424, Feb. 2005.
[13] L.P. Kotra and S. Mobashery, "[Beta]-Lactam Antibiotics, [Beta]-Lactamases and Bacterial Resistance," Bull. de L'institut Pasteur, vol. 96, no. 3, pp. 139-150, http://www. article/B6VKP-3VFH0SY-1/2d389a78b4504261399fa897cf326b9d5 , 1998.
[14] T.P. Smyth, M.E. O'Donnell, M.J. O'Connor, and J.O. StLedger, "Beta-Lactamase-Dependent Prodrugs: Recent Developments," Tetrahedron, vol. 56, no. 31, pp. 5699-5707, 2000.
[15] J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen, and J. Savolainen, "Prodrugs: Design and Clinical Applications," Nature Rev. Drug Discovery, vol. 7, no. 3, pp. 255-270, Mar. 2008.
[16] G.W. Stone, Q. Zhang, R. Castillo, V.R. Doppalapudi, A.R. Bueno, J.Y. Lee, Q. Li, M. Sergeeva, G. Khambatta, and N.H. Georgopapadakou, "Mechanism of Action of NB2001 and NB2030, Novel Antibacterial Agents Activated by Beta-Lactamases," Antimicrobial Agents and Chemotherapy, vol. 48, no. 2, pp. 477-483, Feb. 2004.
[17] K. Bush, M. Macielag, and M. Weidner-Wells, "Taking Inventory: Antibacterial Agents Currently at or Beyond Phase 1," Current Opinion in Microbiology, vol. 7, no. 5, pp. 466-476, Oct. 2004.
[18] J.T. Murphy, R. Walshe, and M. Devocelle, "Modelling the Population Dynamics of Antibiotic-Resistant Bacteria: An Agent-Based Approach," Int'l J. Modern Physics C, vol. 20, no. 3, pp. 435-457, 2009.
[19] N.R. Jennings, K. Sycara, and M.J. Wooldridge, "A Roadmap of Agent Research and Development," Autonomous Agents and Multi-Agent Systems, vol. 1, no. 1, pp. 7-38, 1998.
[20] P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G.L. Drusano, "Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore," Clinical Infectious Diseases, vol. 44, no. 1, pp. 79-86, Jan. 2007.
[21] P. Giesbrecht, T. Kersten, H. Maidhof, and J. Wecke, "Staphylococcal Cell Wall: Morphogenesis and Fatal Variations in the Presence of Penicillin," Microbiology and Molecular Biology Rev., vol. 62, no. 4, pp. 1371-1414, Dec. 1998.
[22] M. Ginovart, D. Lopez, and J. Valls, "Indisim, an Individual-Based Discrete Simulation Model to Study Bacterial Cultures," J. Theoretical Biology, vol. 214, no. 2, pp. 305-319, Jan. 2002.
[23] C. Slater-Radosti, G.V. Aller, R. Greenwood, R. Nicholas, P.M. Keller, W.E.D. Jr., F. Fan, D.J. Payne, and D.D. Jaworski, "Biochemical and Genetic Characterization of the Action of Triclosan on Staphylococcus aureus," The J. Antimicrobial Chemotherapy, vol. 48, no. 1, pp. 1-6, July 2001.
[24] R.A. Lewis, S.P. Curnock, and K.G. Dyke, "Proteolytic Cleavage of the Repressor (Blai) of Beta-Lactamase Synthesis in Staphylococcus Aureus," FEMS Microbiology Letters, vol. 178, no. 2, pp. 271-275, Sept 1999.
[25] Q. Li, J.Y. Lee, R. Castillo, M.S. Hixon, C. Pujol, V.R. Doppalapudi, H.M. Shepard, G.M. Wahl, T.J. Lobl, and M.F. Chan, "NB2001, a Novel Antibacterial Agent with Broad-Spectrum Activity and Enhanced Potency Against Beta-Lactamase-Producing Strains," Antimicrobial Agents and Chemotherapy, vol. 46, no. 5, pp. 1262-1268, May 2002.
[26] M.G. Escalada, A.D. Russell, J.Y. Maillard, and D. Ochs, "Triclosan-Bacteria Interactions: Single or Multiple Target Sites?" Letters in Applied Microbiology, vol. 41, no. 6, pp. 476-481, 2005.
[27] R.D. Jones, H.B. Jampani, J.L. Newman, and A.S. Lee, "Triclosan: A Review of Effectiveness and Safety in Health Care Settings," Am. J. Infection Control, vol. 28, no. 2, pp. 184-196, Apr. 2000.
[28] S.R. Norris, C.W. Stratton, and D.S. Kernodle, "Production of A and C Variants of Staphylococcal Beta-Lactamase by Methicillin-Resistant Strains of Staphylococcus aureus," Antimicrobial Agents and Chemotherapy, vol. 38, no. 7, pp. 1649-1650, July 1994.
14 ms
(Ver 2.0)

Marketing Automation Platform Marketing Automation Tool